When it comes to hair loss, there are as many myths about it as there are treatments for it. An expert broke down common ...
Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results